이노비오, 빌게이츠재단 투자유치 !!
진원생명과학 ( 011000 )
- 빌게이츠 재단이 투자한 위스타 연구소의 지카 백신 프로그램에 선정
- 이노비오, 위스타연구소통한 빌게이츠재단 투자금 유치
Inovio Pharmaceuticals Awarded $6.1 Million Sub-grant Through Wistar Institute to Develop DNA-based Monoclonal Antibodies Against Zika Virus
http://www.nasdaq.com/press-release/inovio-pharmaceuticals-awarded-61-million-subgrant-through-wistar-institute-to-develop-dnabased-20161201-00609
By GlobeNewswire, December 01, 2016, 09:00:00 AM EDT
PLYMOUTH MEETING, Pa. & PHILADELPHIA, Dec. 01, 2016 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) announced today that it has been awarded a $6.1 million sub-grant through The Wistar Institute to develop a DNA-based monoclonal antibody designed to provide a fast-acting treatment against Zika infection and its debilitating effects. The goal of this program, which is funded by a grant to The Wistar Institute from the Bill & Melinda Gates Foundation, is for the researchers to develop a Zika dMAb® therapy ready for human clinical trials in less than two years.